Skip to content

Use of picosecond laser (1064 nm Nd:YAG) in the treatment of Lichen Planus Pigmentosus

To evaluate the efficacy of fractional picosecond 1064 nm Nd:YAG laser in the treatment of Lichen Planus Pigmentosus - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077583
Enrollment
10
Registered
2024-12-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L438- Other lichen planus

Interventions

Intervention1: Fractional picosecond 1064 nm Nd:YAG laser: The following laser parameters will be used: fluence, 0.4-0.8 J/cm2
spot size, 8 mm
approximately 15–20% of pulse overlapping and 1-2 passes. The fluence will be increased on subsequent sessions based on the therapeutic response (pin-point bleeding) and patient tolerability. The expe

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male and female patients in the age group 18-65 years. 2.All patients who are clinically or histologically stable cases of lichen planus pigmentosus. Stability is defined as non-occurrence of new lesions or no increase in the size of existing lesions for the last 6 months. LPP of face or neck 3.Patients not on any other procedures for face/neck

Exclusion criteria

Exclusion criteria: 1.Clinically or histologically active LPP. 2.Patients on systemic treatments for LPP over the past 3 months. 3.Pregnant and lactating women. 4.Hepatic, renal, or any other systemic disease. 5.Patients with any other photosensitive disease or on medications increasing photosensitivity. 6.Patients with keloidal tendency. 7.Patients with unrealistic expectations.

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of fractional picosecond 1064 nm ND:YAG laser in the treatment of Lichen planus pigmentosusTimepoint: After 6 months

Secondary

MeasureTime frame
Pigment Dilution will be assessed at baseline, and before every session 2, 4 and 6 months intervals using QuantifiCare LifeViz® Mini 3D imaging Subjective evaluation: Response to treatment in terms of clearance of pigmentation will be assessed by the dermatologist as follows: - Grade 1 to Grade IVTimepoint: After 6 months

Countries

India

Contacts

Public ContactDr Chaithra Shenoy

CUTIS Academy of Cutaneous Sciences

chaithrashenoy@gmail.com9739247155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026